Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Combretastatin A4
115
CHF
CHF 115.00
In stock
CDX-C0706-M01010 mgCHF 115.00
CDX-C0706-M05050 mgCHF 495.00
| Product Details | |
|---|---|
| Synonyms | 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl) ethane 3,4,5-trimethoxy-3'-hydroxy-4'-methoxystilbene; CA4; CRC 87-09; NSC 817373 |
| Product Type | Chemical |
| Properties | |
| Formula |
C18H20O5 |
| MW | 316.35 |
| CAS | 117048-59-6 |
| Source/Host Chemicals | Plant |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Off-white powder. |
| Solubility | Soluble in DMSO (10mg/ml), ethanol (5mg/ml) or DMF (10mg/ml). Insoluble in water. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | HVXBOLULGPECHP-WAYWQWQTSA-N |
| Smiles | OC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Combretastatin A4 is a natural stilbenoid phenol originally isolated from an African shrub, Combretum caffrum. It is a potent inhibitor of tubulin polymerization and displays strong inhibitory activity on tumor cell growth. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. CA4 was shown to impede tumor growth in several cell lines including IMR32 (neuroblastoma), Hs746T (gastric carcinoma), CFPAC-1 (pancreatic carcinoma) and MCF-7 (breast cancer). It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A-4 is the active component of combretastatin A-4 phosphate, a prodrug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis. Combretastatin A-4 is therefore a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis.
Product References
(1) A.T. McGown & B.W. Fox; Anticancer Drug Des. 3, 249 (1989) | (2) R.T. Dorr, et al.; Invest. New Drugs 14, 131 (1996) | (3) J. Griggs, et al.; Int. J. Oncol. 19, 821 (2001) | (4) J. Griggs, et al.; Lancet Oncol. 2, 82 (2011) (Review) | (5) G.C. Tron, et al.; J. Med. Chem. 49, 3033 (2006) (Review) | (6) L.M. Greene, et al.; Biochem. Pharmacol. 84, 612 (2012) | (7) W. Liang, et al.; Med. Sci. Monit. 22, 4911 (2016)